TT-01688-CL

Main research objectives: 1. To quantitatively analyze the total radioactivity in the excreta of male healthy subjects after a single oral administration of [14C]TT-01688-CL, and obtain the data on the excretion rate of radioactivity in the human body and the main excretion pathway; 2. To investigate the distribution of [14C]TT-01688-CL in whole blood and plasma and the pharmacokinetics of total radioactivity in plasma after a single oral administration of [14C]TT-01688-CL in male healthy subjects; 3. To obtain the radioactive metabolite spectrum in human plasma, urine and feces after oral administration of [14C]TT-01688-CL in male healthy subjects, identify the main metabolites in the human body (≥10% of the total plasma radioactivity AUC), and determine the main biotransformation pathways and elimination pathways of TT-01688-CL in the human body. Secondary study objectives: 1. To quantitatively analyze the concentration of TT-01688-CL and metabolites (if applicable) in plasma using a validated LC-MS/MS method and obtain the pharmacokinetic parameters of TT-01688-CL and metabolites (if applicable) in plasma; 2. To observe the safety of [14C]TT-01688-CL in healthy male subjects after a single dose.